By Drug Target Review2023-12-12T16:00:23
A discovery about Zika’s enzyme, NS2B-NS3, offers promise for therapeutic targets for Zika and other flaviviruses.
Already a member? Sign in
By highlighting cutting-edge research and its practical applications, Drug Target Review enables readers to make decisions that accelerate innovation, translate discoveries into therapies, and create tangible benefits for patients worldwide.
By becoming a member you join a connected and collaborative community driving the industry forward. Member benefits include:
2026-03-31T14:05:00Z
2023-05-23T11:10:47
Sponsored by NanoTemper Technologies
2024-05-10T11:23:31
Sponsored by BellBrook Labs
2025-10-08T14:00:00
Sponsored by Eurofins Discovery
2025-04-22T14:58:00
Sponsored by Takara Bio USA
2023-03-07T10:55:58
Sponsored by Agilent
2023-03-20T13:41:33
Sponsored by Bio-Techne
Site powered by Webvision Cloud